JP MORGAN 2015: Bristol-Myers oncology head boasts PD-1 promise, partners
This article was originally published in Scrip
"The strategy of being able to use immune-oncology to improve outcomes is being realized," Bristol-Myers Squibb head of oncology development Michael Giordano told Scrip on 12 January during the 33rd Annual JP Morgan Healthcare Conference in San Francisco.
You may also be interested in...
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.